Global office locator

On 15 April at 12:00 pm, join ICON’s Alan Baldridge at the GLP‑1‑Based Therapeutics Summit for his session, “Is there anything GLP‑1s can’t do? Unlocking the next generation of metabolic treatments.” He will offer a fo...

An estimated one billion people worldwide will be living with obesity by 2030. Discover how we deliver ready-to-deploy infrastructure, market intelligence, and deep expertise to support early decisions and accelerate h...

Recent findings highlight the continued relevance and reliability of the Oswestry Disability Index instrument for evaluating disability in patients with Degenerative Disc Disease. Study participants demonstrated strong...

Neuroscience programmes demand reliable feasibility, broad patient access, and operational consistency across regions. At ADPD 2026, stop by booth \#29 to learn how ICON combines informatics driven feasibility, extensi...

Clinical trial start-up can be a stubborn bottleneck, where delays can cost time, money, and patient access. ICON’s industry survey and commentary from Brian Mallon, EVP of Site and Patient Solutions, reveal why timeline...

Formulations in early clinical development require a delicate balance of flexibility, simplicity, and scientific rigor. In first‑in‑human trials, dose ranges can vary by 10–100 fold increase between the starting dose a...

Ahead of World Obesity Day tomorrow, explore how ICON successfully supported a sponsors cardiovascular outcome trial for a GLP-1 receptor agonist with 9,900+ patients with type 2 diabetes and maintained a retention rate ...

Human ADME studies are essential for understanding how investigational drugs are absorbed, distributed, metabolised and excreted. Yet traditional sampling—limited to plasma, urine and faeces- leaves a key blind spot: bil...

Join us to explore the latest best practices in global flow cytometry QC and harmonisation. During this webinar hosted by Bioanalysis Zone ICON’s flow cytometry specialists will discuss: - Industry best practices for h...

The FDA recent draft guidance sets out how Bayesian statistical methods can be applied across drug and biologics development. While Bayesian approaches have been used in medical devices and rare diseases, this is the f...

ICON’s Andrew Garrett and Tim Clark discuss the new FDA Bayesian guidance, which marks a shift toward more efficient clinical trials. https://ow.ly/XeAs50YlTf2

Join ICON at #OCT Southeast on 10–11 March to explore how we support biotech organizations with flexible clinical development solutions, operational expertise and data driven decision making. Visit Booth #37 to meet ou...